Merck (NYSE: MRK) topped analysts' consensus earnings estimates every time the company reported quarterly results in 2018. That's one of the reasons why Merck's share price soared nearly 36% last year.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,